Andy Moye, Paige CEO, spoke to MedTech Dive about our work developing cutting-edge diagnostic AI and biomarker AI applications, including HER2Complete, our newly CE-marked tool for uncovering HER2 expression in H&E-stained breast slides. He also shared how we are progressing our mission to enhance patient care through safe and effective AI tools, and how we hope to see the digital pathology landscape evolve over the coming year. “This is human and machine working together. Our studies have shown that pathologists tend to increase their sensitivity by using the AI tool. And so it’s not a replacement, it’s that second read. What we’ve heard from a lot of pathologists, just anecdotally, is that they feel more confident calling something when they have an AI tool available to them.”
Read the full article on MedTech Dive
—
Reuter, E., Taylor, N. P., & Taylor, N. P. (2022, October 7). Friday Q&A: Paige CEO Andy Moye on how digital pathology is changing the diagnostic game. MedTech Dive. https://www.medtechdive.com/news/paige-ceo-digital-pathology-prostate/633597/
